



1639
Box 50

Atty. Docket No.: 8039/1090

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Riechmann, et al.
Serial No.: 09/710,444
Filed: November 10, 2000
Entitled: "Selection System"

Examiner: B. Celsa
Group Art Unit: 1639
Conf. No.: 2736

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Box: Non Fee Amendment, Commissioner for Patents, Washington, D.C. 20231.

Mary Wilson

Name of Person Mailing Paper


Signature of Person Mailing Paper

RECEIVED

Box: Non Fee Amendment
Commissioner for Patents
Washington, D.C. 20231

NOV 19 2002

TECH CENTER 1600/2900

TRANSMITTAL LETTER


Enclosed for filing the above-identified patent application, please find the following documents:

1. Amendment & Response to Notice of Incomplete Reply to Sequence Letter (Bonafide Attempt);
2. Copy of Notice to Comply;
3. Paper Copy of Revised Sequence Listing;
4. Computer Readable Copy of Revised Sequence Listing; and
5. Return Post Card.

No fee is believed necessary for this filing. The Commissioner for Patents is hereby authorized to charge any additional fees or credit any overpayment in the total fees to Deposit Account No. 16-0085, Reference 8039/1090. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Date: November 5, 2002



Name: Mark J. Fitzgerald
Registration No.: 45,928
Palmer & Dodge LLP
111 Huntington Avenue
Boston, MA 02199-7613
Tel: 617-239-0100

RECEIVED


NOV 19 2002

TECH CENTER 1600/2900

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." (see 7. below)
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: NEED SEQ. IDENTIFIERS (PAGE9 ,line 13)

RECEIVED

NOV 19 2002

Applicant Must Provide:

- ☒ An initial or **substitute** computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or **substitute** paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

TECH CENTER 1600/2900